We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

69 hedge funds and large institutions have $133M invested in Applied Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 29 increasing their positions, 16 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more call options, than puts

Call options by funds: $1.1M | Put options by funds: $503K

81% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 16

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.8% less ownership

Funds ownership: 57.71%56.91% (-0.8%)

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

1% less funds holding

Funds holding: 7069 (-1)

47% less capital invested

Capital invested by funds: $251M → $133M (-$117M)

Holders
69
Holders Change
-1
Holders Change %
-1.43%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
29
Reduced
16
Closed
11
Calls
$1.1M
Puts
$503K
Net Calls
+$601K
Net Calls Change
+$923K
Name Holding Trade Value Shares
Change
Change in
Stake
O
1
OrbiMed
New York
$20.7M +$739K +56,294 +2%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$20.1M -$2.19M -166,771 -7%
BlackRock
3
BlackRock
New York
$11.6M +$75K +5,714 +0.4%
Franklin Resources
4
Franklin Resources
California
$10.1M +$3.82M +291,012 +35%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$9.97M +$1.3M +98,729 +10%
KCM
6
Knoll Capital Management
Florida
$9.24M
Vanguard Group
7
Vanguard Group
Pennsylvania
$7.62M +$11K +839 +0.1%
RSCM
8
Rock Springs Capital Management
Maryland
$6.28M
EMFAT
9
Emerald Mutual Fund Advisers Trust
Pennsylvania
$5.66M +$139K +10,605 +2%
EA
10
Emerald Advisers
Pennsylvania
$5.47M +$601K +45,797 +8%
DCM
11
Driehaus Capital Management
Illinois
$4.63M -$1.61M -122,450 -19%
AG
12
Artal Group
Luxembourg
$3.58M
State Street
13
State Street
Massachusetts
$3.06M +$364K +27,700 +9%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$2.71M -$169K -12,851 -4%
Northern Trust
15
Northern Trust
Illinois
$1.59M -$6.82K -519 -0.3%
KPW
16
Kore Private Wealth
New York
$1.12M +$1.64M +125,000 New
Russell Investments Group
17
Russell Investments Group
United Kingdom
$677K +$281K +21,419 +39%
Goldman Sachs
18
Goldman Sachs
New York
$676K +$176K +13,415 +22%
UBS Group
19
UBS Group
Switzerland
$666K +$699K +53,211 +251%
First Manhattan
20
First Manhattan
New York
$660K
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$653K +$299K +22,741 +45%
Millennium Management
22
Millennium Management
New York
$630K +$767K +58,428 +490%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$612K +$12.3K +933 +1%
N
24
Nuveen
North Carolina
$555K -$164K -12,459 -17%
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$541K +$111K +8,485 +16%

APLT Hedge Fund Activity: Q4 2021 in Review

69 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q4 2021, worth a combined $133M — down 47% from $251M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of APLT and 10 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 29 added.

The largest buyer was Franklin Resources, adding an estimated $3.82M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $10.6M sold.

  • 69 institutional investors held Applied Therapeutics (APLT) as of Q4 2021, down from 70 in Q3 2021.
  • Funds reported $133M of Applied Therapeutics stock for Q4 2021, down 47% quarter-over-quarter.
  • 10 funds opened new Applied Therapeutics positions in Q4 2021 and 11 closed out, a net change of -1 holder.
  • The largest Applied Therapeutics buyer in Q4 2021 was Franklin Resources, an estimated $3.82M added.
  • The largest Applied Therapeutics seller in Q4 2021 was Alkeon Capital Management, an estimated $10.6M sold.

Based on aggregated 13F filings for Q4 2021.